Trump announces trade deal with EU following months of negotiations
Investing.com -- Shares of DexCom , Inc. (NASDAQ: DXCM) climbed 9% after the company announced that its Dexcom (NASDAQ:DXCM) G7 15 Day Continuous Glucose Monitoring (CGM) System received FDA clearance for use in adults with diabetes. The new device, which is the longest-lasting and most accurate CGM system according to the company, is expected to set a new standard in glucose monitoring and bolster DexCom's position in the market.
The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The system is designed to extend wear time, reduce waste, and simplify diabetes management. It is also waterproof and can connect directly to an Apple (NASDAQ:AAPL) Watch, allowing users to monitor their glucose levels hands-free.
The approval of the Dexcom G7 15 Day represents a significant advancement for the company, as expressed by Jake Leach, DexCom's executive vice president and chief operating officer. "By listening to the needs of our users, we’re proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in-class technology," Leach stated. He also highlighted the company's anticipation to bring the product to market in the second half of 2025 and encouraged current users to upgrade to their existing G7 system.
DexCom's innovation extends to features like automated activity logging, simplified meal logging, and medication logging, which contribute to a comprehensive understanding of how lifestyle factors affect glucose levels. The system also offers a 12-hour grace period for sensor replacement, integrated mobile app with Dexcom Clarity, and enhanced alert settings for privacy.
As part of its market strategy, DexCom is collaborating with insulin pump partners to ensure compatibility with automated insulin delivery systems upon the launch of the Dexcom G7 15 Day. This strategic move is likely to enhance the product's adoption and integration into diabetes care routines.
The stock's positive movement reflects investor confidence in DexCom's continued leadership and innovation in the glucose monitoring space. With the launch scheduled for the second half of 2025, the company is poised to strengthen its market presence and offer improved diabetes management solutions to its users.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.